Trials in Boston, Massachusetts
Here are the top 10 medical studies for prostate cancer in Boston, Massachusetts
Popular Filters
Phase 3 Trials
Checkpoint Inhibitor
Pembrolizumab + ADT for Prostate Cancer
Recruiting2 awardsPhase 3
Manchester, Connecticut
This trial will test whether a combination of drugs is better than placebo at extending radiographic progression-free survival and overall survival for men with metastatic hormone-sensitive prostate cancer.
Hormone Therapy
Hormone + Radiation Therapy for Prostate Cancer
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial is testing two different intensities of hormone therapy and radiation therapy, comparing them to the current standard of care, in order to determine the best treatment plan for patients with high risk prostate cancer.
AKT Inhibitor
Capivasertib + Abiraterone for Prostate Cancer
Recruiting1 awardPhase 3
Norwich, Connecticut
This trial will compare the efficacy of capivasertib+abiraterone+androgen deprivation therapy to placebo+abiraterone+androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC) whose tumours are PTEN-deficient. The primary endpoint is radiographic progression-free survival.
PARP Inhibitor
Rucaparib + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial is testing if a combination of two drugs, rucaparib and enzalutamide, is better than enzalutamide alone for treating men with prostate cancer that has spread and become resistant to testosterone-deprivation therapy.
Trials With No Placebo
Procedure
Microdevice for Prostate Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing the feasibility of using an MR-guided microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants with prostate cancer who are scheduled for a radical prostatectomy.
Hormone Therapy
Sequential Testosterone + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial tests if alternating high doses of testosterone and enzalutamide can help men with advanced prostate cancer better than just using enzalutamide alone. It targets men whose cancer has continued to progress despite standard treatments. The treatment works by first disrupting the cancer cells with high-dose testosterone, then blocking any remaining cancer cells from using testosterone with enzalutamide. Enzalutamide has been associated with improved overall survival in men with advanced prostate cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.